220247-50-7

Basic information

• Product Name: Methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate
• Synonyms: Methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate;1,2,3,4-Tetrahydro-7-isoquinolinecarboxylic acid methyl ester;7-Isoquinolinecarboxylic acid,1,2,3,4-tetrahydro-,methyl ester;ethyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate
• CAS NO: 220247-50-7
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.22642
• EINECS: -0
• Mol File: 220247-50-7.mol

Chemical Properties

• Boiling Point: 330.171 °C at 760 mmHg
• Flash Point: 153.482 °C
• Appearance: /
• Density: 1.124 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate(220247-50-7)
• EPA Substance Registry System: Methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate(220247-50-7)

Safety Data

• Hazardous Substances Data: 220247-50-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate is used as a key component in the production of several drugs, including antidepressants and antipsychotics, due to its ability to serve as a building block for these pharmaceutical compounds.
Used in Research:
Methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate is used as a research tool to study the activity and reactivity of functional groups in organic chemistry reactions, providing insights into the synthesis and properties of related compounds.
Used in Neuroprotection and Anti-Inflammatory Applications:
Methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate has been studied for its potential neuroprotective and anti-inflammatory properties, indicating its possible use in the development of treatments for neurological disorders and inflammatory conditions.

Upstream product

• 181514-22-7 methyl 4-(2-(2,2,2-trifluoroacetamido)ethyl)benzoate 
• 77265-67-9 4-(2-amino-ethyl)-benzoic acid methyl ester 
• 181514-36-3 methyl 2-(2, 2, 2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxylate 
• 960305-54-8 2-tert-butyl 7-methyl 3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate 
• 67-56-1 methanol 
• 149355-52-2 7-cyano-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 1038549-50-6 2-methyl-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid methyl ester 
• 1397226-71-9 methyl 2-(2,3-diphenylacryloyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxylate 
• 1397226-93-5 methyl 2-(2-(4-fluorophenyl)-3-phenylallyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxylate 
• 220247-69-8 methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate hydrochloride 
• 1003934-57-3 methyl 2-[1-(benzyloxy)-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]-1,2,3,4-tetrahydroisoquinoline-7-carboxylate 

Relevant articles and documents

Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors

The structure-based design of 1, 2, 3, 4-tetrahydroisoquinoline derivatives as selective DDR1 inhibitors is reported. One of the representative compounds, 6j, binds to DDR1 with a Kd value of 4.7 nM and suppresses its kinase activity with an IC50 value of 9.4 nM, but it is significantly less potent for a panel of 400 nonmutated kinases. 6j also demonstrated reasonable pharmacokinetic properties and a promising oral therapeutic effect in a bleomycin-induced mouse pulmonary fibrosis model.

HISTONE DEACETYLASE INHIBITORS

Provided herein are isoform selective histone deacetylase inhibitors of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and compositions thereof. These compounds are isoform selective inhibitors of HDACs and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth such as cancer, malignant tumors, autoimmune diseases, skin diseases, fungal infections, protozoal infections, HIV, inflammation and CNS disorders.

Substituted Spiroamide Compounds

Substituted spiroamide compounds corresponding to formula (I): wherein A, B, Q1, Q2, Q3, Q4, R1, R8, R9a, R9b, R12, R13, R200 and R210 have defined meanings, processes for their preparation, pharmaceutical compositions containing such compounds, and the use of such compounds for treating or inhibiting pain or other conditions mediated at least in part by the bradykinin 1 receptor (B1R).

Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds

Compounds of a certain formula I wherein R1, R2, R3, X, Y, r, s, t, u and v have the meanings as defined in the specification, and the salts, solvates and hydrates thereof are novel effective HDAC 6 inhibitors.

ENZYME INHIBITORS

Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2is the side chain of a natural or non-natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(O)NR3-, -C(=S)-NR3 , -C(=NH)NR3 or -S(=O)2NR3- wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1 , Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula -X2-Q1- or -Q1-X2- wherein X2 is -O-, S- or NRA- wherein RA is hydrogen or optionally substituted C1-C3 alkyl, and Q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members, AIk1 and AIk2 independently represent optionally substituted divalent C3-C7 cycloalkyl radicals, or optionally substituted straight or branched, C1-C6 alkylene, C2-C6 alkenylene ,or C2-C6 alkynylene radicals which may optionally contain or terminate in an ether (-O-), thioether (-S-) or amino (-NRA-) link wherein RA is hydrogen or optionally substituted C1-C3 alkyl; X1 represents a bond; -C(=O); or -S(=O)2-; -NR4C(=O)-, -C(=O)NR4-, -NR4C(=O)NR5- , -NR4S(=O)2-, or -S(=O)2NR4-wherein R4 and R5 are independently hydrogen or optionally substituted C1-C6 alkyl; z is 0 or 1 ; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals R1R2NH-Y-L1-X1-[CH2]Z- and HONHCO-[LINKER]- are attached different ring atoms; and -[Linker]- represents a divalent linker radical linking a ring atom in A with the hydroxamic acid group CONHOH, the length of the linker radical, from the terminal atom linked to the ring atom of A to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.

Synthesis, biochemical evaluation, and classical and three-dimensional quantitative structure-activity relationship studies of 7-substituted- 1,2,3,4-tetrahydroisoquinolines and their relative affinities toward phenylethanolamine N-methyltransferase and t

7-Substituted-1,2,3,4-tetrahydroisoquinolines (7-substituted-THIQs) are potent inhibitors of phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28), the enzyme involved in the biosynthesis of epinephrine. Unfortunately, most of these compounds also ex